An intended consequence of the significant investment to characterize the mammalian genome, and its alterations in neoplastic diseases, has been the discovery and commercialization of new approaches to anticancer therapy. As a result, the list of available targets, formerly directed against the processes of DNA replication and mitosis, or in hormonal regulation of growth of tissue, has been dramatically extended. Many of the newer targets represent normal or aberrant signaling pathways, and are present within the cancer cell as second messengers, on its surface (as receptors), or in the external milieu (as ligands). These targets are, therefore, important to the cancer cell phenotype, and affect proliferation, differentiation, and death options for the cell. Another group of targets encompass the cancer cell's relationship to the tissue environment (both stroma and nonneoplastic cells). These targets involve interactions with blood supply (angiogenesis), immune function (evasion), and matrix (invasion and metastasis). Thus, most targets are directly or indirectly critical to some aspect of cancer cell physiology, although a few additional targets are being approached as localization signals for the delivery of otherwise less specific chemotherapeutic or radiotherapeutic agents. The development of new therapeutic approaches has expanded the scope of research required to characterize the mechanism of action for anticancer agents in preclinical models and in clinical trials. In preclinical research, mechanism of action studies have supported the selection of therapeutic agents, appropriate models of efficacy, and experimental design, as well as rational characterization and prediction of nontumor (host) effects. In clinical research, mechanism of action studies have supported the identification of surrogate markers of efficacy (critical for determining adequacy of dose and latency of response), and the selection of patient subpopulations and tumor subtypes most likely to exhibit clinical responses. Finally, information on mechanism of action may suggest strategies for combination therapies and predict potential mechanisms of disease resistance to therapy.
Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Manuel Mascaro, J., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., Nicholson, R.I., and Baselga, J. (2002). Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol20(1), 110—24.
2.
Arteaga, C.L. (2002). Epidermal growth factor receptor dependence in human tumors: more than just expression?Oncologist7(Suppl. 4), 31—39.
3.
Augen, J. (2002). Industrialized molecular biology, information biotechnology, and the blockbuster drug model—alive and well at age 50. Drug Discovery Today7, S157—9.
4.
Awada, A., Eskens, F.A.L.M., Piccart, M., Cutler, D.L., Van der Gaast, A., Bleiberg, H., Wanders, J., Faber, M.N., Statkevich, P., Fumoleau, P., and Verweij, J. (2002). Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. European J Cancer38(17), 2272—8.
5.
Baselga, J., and Albanell, J. (2002). Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North America16(5), 1041—63.
6.
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D.G., Kaye, S.B., Gianni, L., Harris, A., Bjork, T., Averbuch, S.D., Feyereislova, A., Swaisland, H., Rojo, F., and Albanell, J. (2002). Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol20(21), 4292—302.
7.
Bottaro, D.P., and Liotta, L.A. (2003). Cancer: out of air is not out of action. Nature423(6940), 593—5.
8.
Bruns, C.J., Harbison, M.T., Davis, D.W., Portera, C.A., Tsan, R., McConkey, D.J., Evans, D.B., Abbruzzese, J.L., Hicklin, D.J., and Radinsky, R. (2000). Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res6(5), 1936—48.
9.
Busam, K.J., Capodieci, P., Motzer, R., Kiehn, T., Phelan, D., and Halpern, A.C. (2001). Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol144(6), 1169— 76.
10.
Chan, K.C., Knox, W.F., Gee, J.M., Morris, J., Nicholson, R.I., Potten, C.S., and Bundred, N.J. (2002). Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast . Cancer Res62(1), 122—8.
11.
Clark, G.M., Perez-Soler, R., Siu, L., Gordon, A., and Santabarbara, P. (2003). Rash severity is predictive of increased survival with erlotinib HCI. Meeting Proceedings, Amer Soc Clin Oncol22, Abstract 786.
12.
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Dets, D., Mueser, M., Harstick, A., and Van Cutsem, E. (2003). Cetuximab (C225) alone or in combination with irinotecan (CTP-11) in patients with epidermal growth factor receptor (EGRF)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC ). Meeting Procedings, Amer Soc Clin Oncol 22, Abstract 1012.
13.
Dillman, R.O. (1999). Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer. Cancer Biother Radiopharm14(1), 5—10.
14.
Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med285(21), 1182—6.
15.
Gee, M.S., Procopio, W.N., Makonnen, S., Feldman, M.D., Yeilding, N.M., and Lee, W.M.F. (2003). Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Amer J Pathol162(1), 183—93.
16.
Grunwald, V., and Hidalgo, M. (2003). Development of the epidermal growth factor receptor inhibitor OSI-774. Sem Oncol30(3 Suppl. 6), 23—31.
17.
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell100(1), 57—70.
Kris, R.M., Lax, I., Gullick, W., Waterfield, M.D., Ullrich, A., Fridkin, M., and Schlessinger, J. (1985). Antibodies against a synthetic peptide as a probe for the kinase activity of the avian EGF receptor and verbB protein. Cell40(3), 619—25.
20.
Kurebayashi, J. (2001). Biological and clinical significance of HER2 overexpression in breast cancer. Breast Cancer8(1), 45—51.
21.
Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V., and Ferrara, N. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science246(4935), 1306—9.
22.
Lin, C.R., Chen, W.S., Kruiger, W., Stolarsky, L.S., Weber, W., Evans, R.R., Verma, I.M., Gill, G.N., and Rosenfeld, M.G. (1984). Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells . Science224(4651), 843—8.
23.
Madhusudan, S., and Harris, A. (2002). Drug inhibition of angiogenesis. Curr Opin Pharmacol2(4), 403—14.
24.
McCarthy, M. (2003). Antiangiogenesis drug promising for metastatic colorectal cancer. New treatments for colorectal cancer might improve patients' survival, investigators reported at ASCO. Lancet361(9373), 1959.
25.
Muhsin, M., Graham, J., and Kirkpatrick, P. (2003). Gefitinib. Nature Rev Drug Discov2, 515—6.
26.
National Cancer Institute. (2002). Fact Book, Author: Bethesda, Maryland .
27.
Nimmanapalli, R., and Bhalla, K. (2002). Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias. Curr Opin Oncol14(6), 616—20.
28.
Nishikawa, R., Ji, X.-D., Harmon, R.C., Lazar, C.S., Gill, G.N., Cavenee, W.K., and Huang, H.-J. S. (1994). A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA91(16), 7727—31.
29.
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., and Comoglio, P.M. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell3(4), 347—61.
30.
Pharmaceutical Research and Manufacturers of America (PhRMA). (2003). Pharmaceutical Industry Profile. PhRMA, Washington, DC.
31.
Reinmuth, N., Liu, W., Ahmad, S.A., Fan, F., Stoeltzing, O., Parikh, A.A., Bucana, C.D., Gallick, G.E., Nickols, M.A., Westlin, W.F., and Ellis, L.M. (2003). Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res63, 2079—87.
32.
Reynolds, T. (2002). Biotech firm faces challenges from FDA, falling stock prices. J Nat Cancer Inst94(5), 326—8.
33.
Ritter, C.A., and Arteaga, C.L. (2003). The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Seminars Oncol30(Suppl. 1), 3—11.
34.
Saltz, L., Kies, M., Abbruzzese, J.L., Azarnia, N., and Needle, M. (2003). The presence and intensity of the Cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Meeting Proceedings, Amer Soc Clin Oncol22, Abstract 817.
35.
Schlingemann, R.O., Rietveld, F.J., Kwaspen, F., van de Kerkhof, P. C., de Waal, R. M., and Ruiter, D. J. (1991). Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue . Am J Pathol138(6), 1335—47.
36.
Sebolt-Leopold, J.S. (2000). Development of anticancer drugs targeting the MAP kinase pathway. Oncogene19(56), 6594—9.
37.
Shaheen, R.M., Davis, D.W., Liu, W., Zebrowski, B.K., Wilson, M.R., Bucana, C.D., McConkey, D.J., McMahon, G., and Ellis, L.M. (1999). Antiangiogenic therapy targeting the tyrosine kinase receptorfor vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res59(21), 5412—6.
38.
Sirotnak, F.M., Zakowski, M.F., Miller, V.A., Scher, H.I., and Kris, M.G. (2000). Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res6(12), 4885— 92.
39.
Sorbera, L.A., Castaner, J., Silvestre, J.S., and Bayes, M. (2002). Erlotinib hydrochloride. Oncolytic EGF receptor inhibitor. Drugs Future27(10), 923—34.
40.
Spaulding, D.C., and Spaulding, B.O. (2002). Epidermal growth factor receptor expression and measurement in solid tumors. Semi Oncol29(5 Suppl. 14), 45—54.
41.
Traxler, P. (2003). Tyrosine kinases as targets in cancer therapy—successes and failures. Expert Opin Therap Targets7(2), 215—34.
42.
Wong, A.J., Ruppert, J.M., Bigner, S.H., Grzeschik, C.H., Humphrey, P.A., Bigner, D.S., and Vogelstein, B. (1992). Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Nat Acad Sci USA89(7), 2965—9.
